Related Experiment Video
Updated: Feb 20, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.5K
CDK5 in oncology: recent advances and future prospects
Jimma Likisa Lenjisa1, Solomon Tadesse1, Nishat Zareen Khair1
1Centre for Drug Discovery & Development, Sansom Institute for Health Research, School of Pharmacy & Medical Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Future Medicinal Chemistry
|October 28, 2017
Summary
Targeting cyclin-dependent kinases (CDK) is key for cancer therapy. This review focuses on CDK5 (cyclin-dependent kinase 5), exploring its role in cancer and potential as a drug target for developing novel cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) are critical regulators of the cell cycle, and their dysregulation is implicated in cancer.
- CDK5, traditionally known for its role in neurobiology, is increasingly recognized for its involvement in various cancers.
- Aberrant CDK5 expression is linked to the initiation and progression of both solid tumors and hematological malignancies, as well as cancer stem cell regulation.
Purpose of the Study:
- To review the current understanding of CDK5 as a potential therapeutic target in cancer treatment.
- To highlight the role of CDK5 in oncogenesis and cancer stem cell biology.
- To provide insights into the development of selective CDK5 inhibitors for cancer therapy.
Main Methods:
- Literature review of recent studies on CDK5 in cancer.
- Analysis of CDK5's role in different cancer types and cancer stem cell regulation.
- Discussion of strategies for designing potent and selective CDK5 inhibitors.
Main Results:
- CDK5 plays a significant role in the development and progression of multiple cancers.
- CDK5 is implicated in the maintenance and function of cancer stem cells.
- The development of selective CDK5 inhibitors presents a promising therapeutic avenue.
Conclusions:
- CDK5 is an attractive and druggable target for novel cancer therapies.
- Targeting CDK5 may offer a new strategy for treating various malignancies, including those resistant to conventional therapies.
- Further research into selective CDK5 inhibition is warranted to translate this potential into clinical benefits.
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
02:39Positive Regulator Molecules
7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
02:18Cancer
54.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.7K